Search Result
Results for "
drug induced liver injury
" in MedChemExpress (MCE) Product Catalog:
2
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-110267
-
DY268
3 Publications Verification
|
FXR
|
Metabolic Disease
|
|
DY268 is a farnesoid X receptor (FXR) antagonist (IC50=7.5 nM). It inhibits FXR transactivation in a cell-based assay with an IC50 value of 468 nM. DY268 can be used in the study of drug-induced liver injury (DILI) .
|
-
-
- HY-N0010
-
|
|
FXR
Sirtuin
TNF Receptor
Interleukin Related
|
Metabolic Disease
|
|
Geniposidic acid is an orally active FXR modulator and SIRT6 activator. Geniposidic acid binds to the Ser332 and His447 sites on the FXR ligand-binding domain, thereby driving nuclear translocation, coactivator recruitment, and transcription of downstream bile acid and cholesterol metabolism-related genes. Geniposidic acid improves metabolic dysfunction-related fatty liver disease by activating the SIRT6 signaling pathway. Geniposidic acid inhibits inflammation and modulates gut microbiota to alleviate colitis. Geniposidic acid can be used in research on drug-induced liver injury, inflammatory bowel disease, metabolic dysfunction-related fatty liver disease, and metabolic dysfunction-related steatohepatitis .
|
-
-
- HY-108292
-
|
|
NF-κB
|
Neurological Disease
Cancer
|
|
Propacetamol hydrochloride is an orally active prodrug of paracetamol and an inducer of acute liver injury models, with multiple properties including antinociception, antioxidation and gastroprotection. Propacetamol hydrochloride potentiates Tramadol and attenuates Aspirin (HY-14654)-induced gastric mucosal damage and lipid peroxidation. Under specific conditions, Propacetamol hydrochloride also acts as a hepatotoxic inducer, triggering acute liver injury, oxidative stress and apoptosis, with strain differences in toxicity sensitivity. Propacetamol hydrochloride can be used in the research of acute liver injury, drug-induced hepatotoxicity and gastric mucosal damage .
|
-
-
- HY-N5073
-
|
4''-O-Glucosylvitexin
|
JNK
p38 MAPK
Interleukin Related
TNF Receptor
Caspase
Lactate Dehydrogenase
Apoptosis
|
Cardiovascular Disease
Metabolic Disease
|
|
Vitexin-4''-O-glucoside (4''-O-Glucosylvitexin) is an orally active natural flavonoid component with multiple pharmacological effects including antioxidation, anti-inflammation, cytoprotection and anti-apoptosis. Vitexin-4''-O-glucoside regulates the MAPK signaling pathway by downregulating the phosphorylation levels of JNK and p38, thereby blocking endoplasmic reticulum stress responses. Vitexin-4''-O-glucoside alleviates oxidative stress by reducing MDA content and upregulating the activities of SOD and CAT, attenuates inflammation by downregulating the expressions of inflammatory factors TNF-α, IL-1β and IL-6, and also reduces LDH release and inhibits caspase-3 activation. Vitexin-4''-O-glucoside effectively improves drug-induced acute liver injury and exerts significant protective effects against myocardial hypoxia/reoxygenation injury. Vitexin-4''-O-glucoside can be used in studies on acute liver injury, cardiovascular diseases and myocardial hypoxia-reoxygenation injury .
|
-
-
- HY-E70398
-
|
L-Iditol dehydrogenase; Polyol dehydrogenase; SDH
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
Sorbitol dehydrogenase (L-Iditol dehydrogenase) is an oxidoreductasea and catalyses the conversion of sorbitol to fructose with NAD + as the coenzyme. Sorbitol dehydrogenase catalyses pH-dependent redox reactions between NAD +/NADH and sorbitol/fructose. Sorbitol dehydrogenase is implicated in diabetic complications and is a biomarker of drug-induced liver injury. Sorbitol dehydrogenase can be used for the research of diabetes and liver injury .
|
-
-
- HY-D3000
-
|
|
Fluorescent Dye
|
Metabolic Disease
|
|
NIR-RED ROS-H2O2 Probe is a near-infrared fluorescent probe used for detecting hydrogen peroxide (H₂O₂) and featuring dual-modal fluorescence/photoacoustic imaging capabilities. NIR-RED ROS-H2O2 Probe successfully detects the upregulated fluorescence signal of H₂O₂ in HepG2 cells and a mouse liver injury model. NIR-RED ROS-H2O2 Probe can be used as a biomarker detection tool for drug-induced liver injury (DILI) .
|
-
-
- HY-D2999
-
|
|
Fluorescent Dye
|
Metabolic Disease
|
|
NIR-RED ATP Probe is a NIR-II fluorescent probe. NIR-RED ATP Probe exhibits high affinity and selectivity for ATP and can non-invasively and with high contrast detect changes in ATP concentration at the cellular level, with minimal interference to the abundant biomolecules within the cells. NIR-RED ATP Probe can be used as a biomarker detection tool for drug-induced liver injury (DILI) .
|
-
-
- HY-D3002
-
|
|
Fluorescent Dye
|
Metabolic Disease
|
|
ONOO-/O2- tracker probe is a dual-responsive near-infrared fluorescent probe. ONOO-/O2- tracker probe will only emit a strong fluorescence signal when both peroxynitrite (ONOO⁻) and superoxide anion (O₂•⁻), the two key reactive oxygen/nitrogen species, are present simultaneously. ONOO-/O2- tracker probe can be used as a biomarker detection tool for drug-induced liver injury (DILI) .
|
-
-
- HY-162220
-
|
|
Estrogen Receptor/ERR
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-94 (Compound 12) is an effective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for Estradiol (HY-B0141). HSD17B13-IN-94 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD, NASH, or drug-induced liver injury (DILI) .
|
-
-
- HY-168332
-
|
|
FXR
|
Metabolic Disease
|
|
FXR agonist 11 (Compound 14) is an FXR agonist with an EC50 of 1.2 μM and a maximum effect of 73.7%. FXR agonist 11 can significantly increase GSH levels in the liver and is used to study drug-induced liver injury diseases .
|
-
-
- HY-161227
-
|
|
17β-HSD
|
Metabolic Disease
Inflammation/Immunology
|
|
HSD17B13-IN-43 is a selective inhibitor of HSD17B13 that competitively blocks the activity of this enzyme. HSD17B13-IN-43 exhibits an IC50 ≤ 0.1 µM in in vitro assays. HSD17B13-IN-43 can be used in studies of non-alcoholic steatohepatitis, fatty liver disease and hepatic fibrosis .
|
-
-
- HY-157613
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-5 (Compound 96) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a Ki value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-5 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
|
-
-
- HY-157601
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-4 (Compound 95) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a Ki value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-4 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
|
-
-
- HY-163243
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-29 (Compound 53) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-29 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-163249
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-49 (Compound 81) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-49 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-161229
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-69 (Compound 11) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-69 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-162223
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-97 (compound 4) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor with an IC50 value of ≤0.1 µM. HSD17B13-IN-97 has the potential for the research of Nonalcoholic fatty liver diseases (NAFLDs), nonalcoholic steatohepatitis (NASH) or or drug induced liver injury (DILI) .
|
-
-
- HY-162213
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-86 (Compound 188) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-86 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-163251
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-52 (Compound 84) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-52 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-163261
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-66 (Compound 146) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-66 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-162210
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-65 (Compound 168) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-65 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-161230
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-75 (Compound 21) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-75 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-162209
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-63 (Compound 160) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-63 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-163254
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-57 (Compound 93) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-57 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-163263
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-80 (Compound 151) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-80 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-163264
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-81 (Compound 154) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-81 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-157662
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-33 (Compound 115) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-33 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-163252
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-53 (Compound 88) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-53 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-163266
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-83 (Compound 150) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-83 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-163253
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-56 (Compound 89) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-163250
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-51 (Compound 82) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-51 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-161228
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-48 (Compound 12) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-48 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-163265
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-82 (Compound 156) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-82 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-163262
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-71 (Compound 149) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-71 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-162208
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-55 (Compound 167) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-55 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-163258
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-61 (Compound 132) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-61 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-162207
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-54 (Compound 158) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-54 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-161232
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-79 (Compound 32) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-79 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-163260
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-64 (Compound 143) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-64 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-162225
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-99 (Compound 6) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-99 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-163257
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-60 (Compound 126) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-60 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-163256
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-59 (Compound 177) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-59 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-161216
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-15 (Compound 6) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. HSD17B13-IN-15 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
|
-
-
- HY-163245
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-32(Compound 67) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-32can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-161215
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-14 (Compound 4) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. HSD17B13-IN-14 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
|
-
-
- HY-161214
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-12 (Compound 3) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for both leukotriene B3 and estradiol. HSD17B13-IN-12 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
|
-
-
- HY-161213
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-11 (Compound 2) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. HSD17B13-IN-11 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
|
-
-
- HY-162219
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-93 (Compound 9) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value for estradiol that is greater than 0.1 μM and less than or equal to 0.5 μM. HSD17B13-IN-93 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-162217
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-91 (Compound 5) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value for estradiol that is greater than 0.1 μM and less than or equal to 0.5 μM. HSD17B13-IN-91 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-163253S
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-56-D3 (Compound 169) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56-D3 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
- HY-163263S1
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-80-d2 (Compound 200) is the the deuterium labeled HSD17B13-IN-80 (HY-163263). HSD17B13-IN-80 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-80 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
- HY-N11733
-
|
|
Bacterial
|
Infection
|
|
D-Glucoheptose is a heptose monosaccharide that serves as a starting material for sedoheptulose. D-Glucoheptose has a strong association with the genus Symbiobacterium. The content of D-Glucoheptose in urine of the control group without liver injury is higher than that in the anti-tuberculosis drug-induced liver injury group. D-Glucoheptose can be used in studies related to anti-tuberculosis drug-induced liver injury .
|
-
- HY-D3191
-
|
|
Fluorescent Dye
Aminopeptidase
Monoamine Oxidase
|
Infection
Metabolic Disease
|
|
L&M-D-MR is a highly specific fluorescent "AND" logic probe with response moieties for leucine aminopeptidase (LAP) and monoamine oxidase (MAO). The coexistence of both LAP and MAO is required for L&M-D-MR to trigger intramolecular cyclization, release fluorophores and activate fluorescence. In the presence of only a single enzyme, L&M-D-MR generates only an extremely weak signal. L&M-D-MR enables bioimaging in living cells and mouse models, and can effectively distinguish different subtypes of liver diseases via blood samples or test strips. L&M-D-MR is widely used in studies related to liver cirrhosis, hepatitis B and drug-induced liver injury .
|
-
-
-
HY-L076
-
|
|
643 compounds
|
|
Drug-induced liver injury (DILI; also known as drug-induced hepatotoxicity) is caused by medications (prescription or OTC), herbal and dietary supplements (HDS), or other xenobiotics that result in abnormalities in liver tests or in hepatic dysfunction that cannot be explained by other causes. Drugs are an important cause of liver injury. Drug-induced hepatic injury is the most common reason cited for withdrawal of an approved drug.
DILI is thought to occur via several different mechanisms. Among these are direct impairment of the structural (e.g., mitochondrial dysfunction) and functional integrity of the liver; production of a metabolite that alters hepatocellular structure and function; production of a reactive drug metabolite that binds to hepatic proteins to produce new antigenic drug-protein adducts, which are targeted by hosts’ defenses (the hapten hypothesis); and initiation of a systemic hypersensitivity response (i.e., drug allergy) that damages the liver.
MCE Drug-induced Liver Injury (DILI) Compound Library contains a unique collection of 643 hepatotoxicity causing compounds and is a powerful tool to research DILI and other drug toxicities. This library can be used to understand the mechanisms of DILI, identify biomarkers for early DILI prediction, and allow timely recognition during drug development, thus finally achieving successful DILI prevention and assessment in the pre-marketing phase.
|
| Cat. No. |
Product Name |
Type |
-
- HY-D3000
-
|
|
Fluorescent Dyes
|
|
NIR-RED ROS-H2O2 Probe is a near-infrared fluorescent probe used for detecting hydrogen peroxide (H₂O₂) and featuring dual-modal fluorescence/photoacoustic imaging capabilities. NIR-RED ROS-H2O2 Probe successfully detects the upregulated fluorescence signal of H₂O₂ in HepG2 cells and a mouse liver injury model. NIR-RED ROS-H2O2 Probe can be used as a biomarker detection tool for drug-induced liver injury (DILI) .
|
-
- HY-D2999
-
|
|
Fluorescent Dyes
|
|
NIR-RED ATP Probe is a NIR-II fluorescent probe. NIR-RED ATP Probe exhibits high affinity and selectivity for ATP and can non-invasively and with high contrast detect changes in ATP concentration at the cellular level, with minimal interference to the abundant biomolecules within the cells. NIR-RED ATP Probe can be used as a biomarker detection tool for drug-induced liver injury (DILI) .
|
-
- HY-D3002
-
|
|
Fluorescent Dyes
|
|
ONOO-/O2- tracker probe is a dual-responsive near-infrared fluorescent probe. ONOO-/O2- tracker probe will only emit a strong fluorescence signal when both peroxynitrite (ONOO⁻) and superoxide anion (O₂•⁻), the two key reactive oxygen/nitrogen species, are present simultaneously. ONOO-/O2- tracker probe can be used as a biomarker detection tool for drug-induced liver injury (DILI) .
|
-
- HY-D3191
-
|
|
Fluorescent Dyes
|
|
L&M-D-MR is a highly specific fluorescent "AND" logic probe with response moieties for leucine aminopeptidase (LAP) and monoamine oxidase (MAO). The coexistence of both LAP and MAO is required for L&M-D-MR to trigger intramolecular cyclization, release fluorophores and activate fluorescence. In the presence of only a single enzyme, L&M-D-MR generates only an extremely weak signal. L&M-D-MR enables bioimaging in living cells and mouse models, and can effectively distinguish different subtypes of liver diseases via blood samples or test strips. L&M-D-MR is widely used in studies related to liver cirrhosis, hepatitis B and drug-induced liver injury .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-163253S
-
|
|
|
HSD17B13-IN-56-D3 (Compound 169) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56-D3 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
-
- HY-163263S1
-
|
|
|
HSD17B13-IN-80-d2 (Compound 200) is the the deuterium labeled HSD17B13-IN-80 (HY-163263). HSD17B13-IN-80 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-80 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
